A number of other brokerages have also commented on CGIX. Zacks Investment Research lowered shares of Cancer Genetics from a hold rating to a sell rating in a report on Wednesday, October 4th. ValuEngine cut shares of Cancer Genetics from a sell rating to a strong sell rating in a research note on Friday, December 1st. Finally, Maxim Group assumed coverage on shares of Cancer Genetics in a research note on Thursday, December 7th. They issued a buy rating and a $6.00 price objective for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Cancer Genetics presently has a consensus rating of Hold and an average target price of $5.56.
Shares of Cancer Genetics (NASDAQ:CGIX) traded down $0.05 during trading hours on Tuesday, hitting $1.90. 73,502 shares of the stock were exchanged, compared to its average volume of 222,849. The company has a market cap of $54.02, a price-to-earnings ratio of -1.96 and a beta of 1.11. Cancer Genetics has a 1 year low of $1.70 and a 1 year high of $5.30. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.18.
In other Cancer Genetics news, Director John Pappajohn acquired 150,000 shares of the business’s stock in a transaction dated Friday, December 8th. The stock was bought at an average price of $1.86 per share, with a total value of $279,000.00. Following the purchase, the director now owns 2,781,204 shares of the company’s stock, valued at $5,173,039.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 21.30% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the company. Northern Trust Corp boosted its stake in shares of Cancer Genetics by 61.0% in the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after purchasing an additional 12,168 shares in the last quarter. Granahan Investment Management Inc. MA boosted its stake in shares of Cancer Genetics by 26.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after purchasing an additional 49,371 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Cancer Genetics by 61.9% in the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after purchasing an additional 197,619 shares in the last quarter. 11.13% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Cancer Genetics (CGIX) PT Set at $6.00 by HC Wainwright” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2018/01/20/cancer-genetics-cgix-pt-set-at-6-00-by-hc-wainwright.html.
Cancer Genetics Company Profile
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.